Combination therapies based on the copper chelator TM (e.g., synergistic LOX/TGF-β inhibitors) have the potential to reduce tumour resistance to copper depletion by effectively overcoming adaptive resistance. This evidence concerns the gene TGFB1 and neoplasm.